Vemurafenib resistance in melanoma provides a successful example of such an approach: only four years after the first landmark study showing the benefits of vemurafenib in BRAFV600E-mutant melanoma [7], a combination with an MEK inhibitor [10] (MEK activation is a frequent cause of vemurafenib resistance) was approved by the FDA and shown to improve PFS and OS in a 2014 phase III trial [11]. Here, MAP2K7 is linked to melanoma.